TW EN

scroll

Go Top

Overview

TCTC

CAKs integrates several clinical trial sites in Taiwan, providing standardized clinical trial protocol, ensuring clinical trial quality and adherence. CAKs have credibility to provide trustworthy clinical trial data and promote the international clinical trial for kidney disease in Taiwan.

CAKs is dedicated to

1.Share the clinical data and research result..

2.Promote clinical related research for new medication, medical equipment, and medical technique for kidney disease in Taiwan.

Strengths

TCTC

1.Acute kidney injury

2. kidney disease

Major Achievements

TCTC

Academic achievements︰

  • TCTC worked with other five medical societies, including Taiwan Society of Nephrology, Taiwan Society of Critical Care Medicine, Taiwan Society of Emergency and Critical Care medicine, Taiwan Society for Parental and Enteral nutrition and completed the "2020 Taiwan Acute Kidney Injury Treatment Consensus" in 2020. The submission of consensus on medical journal and the result had been published in 2021
  • Taiwan Society of Critical Care Medicine held the "Comprehensive Intensive Care Advanced Course": Post AKI care and the new trend of sepsis blood purification on 2021/3/6.
  • Professor Yung-Chang Chen, our Secretary-General, was invited by Ministry of Health and Welfare to report on acute kidney injury and dialysis treatment on June 19, 2021.
 

Technical achievements︰

  • Professor Yung-Chang Chen and Professor Jan-Jung Hong of Tsinghua University developed biomedical chip detecting NGAL and won the 2019 Future Science and Technology Breakthrough Award. They also received a 3-year grant from Ministry of Science and Technology for “Improving the accuracy of predicting acute kidney injury with a new biomarker kit” They use new combination of biomarkers (NGAL, IL-18 and KIM-1) in microfluidic biomedical sensor chip for detecting acute kidney injury.and the system has clinical application for point of care use, which can detect acute kidney injury biomarkers with a single drop of blood.
  • TCTC has a biomedical industry cooperation project for domestic manufacturers: an intelligent cardiac-thoracic ratio estimation system. Intellectual Cardiothoracic ratio (iCTR) is a simple and non-invasive tool that can detect the size of the heart and often used to check for cardiac hypertrophy. However, the traditional calculation of the cardio-thoracic ratio is time consuming. Therefore, this experimental project is mainly to verify whether the iCTR estimation system using machine learning is as accurate as traditional method.
 

Economic benefits:

Through the "multidisciplinary post-acute kidney injury study ", we would acquire domestic data first-handed. If the follow-up study result is positive, domestic pharmacy that producing therapeutic drug ACEi/ARB may be benefited. TCTC would also negotiate further clinical trial with domestic pharmacy. The result would also benefit post AKI CKD patients.

 

Social benefits︰

TCTC is currently discussing with the local manufacturer Panion & BF Biotech for clinical trial of PBF 1681 as a treatment for iron deficiency anemia in non-dialysis patients with chronic kidney disease. Such patients are more suitable to use oral iron. However, traditional iron supplements (such as ferrous sulfate, ferrous fumarate, or ferrous gluconate) are difficult to absorbed by intestine. Side effect of these traditional agent are obvious and are not well tolerated. There is a great need to develop an effective and well-tolerated novel oral iron agent to treat NDD-CKD patients with iron deficiency anemia, to avoid concurrent use of intravenous iron and/or erythropoiesis stimulant agent. PBF-1681 (Pharmaceutical Grade Ferric Citrate) is a drug candidate.

Members

TCTC

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Kaohsiung Medical University Hospital /Division of Nephrology

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Linkou Chang Gung Memorial Hospital/Division of Nephrology

Keelung Chang Gung Memorial Hospital/Division of Nephrology

Kaohsiung Chang Gung Memorial Hospital/Division of Nephrology

National Taiwan University Hospital /Division of Nephrology

National Taiwan University Hospital /Division of Nephrology

National Taiwan University Hospital /Division of Nephrology

Taipei Veterans General Hospital /Division of Nephrology

Taipei Veterans General Hospital /Division of Nephrology

Taipei Veterans General Hospital /Division of Nephrology

Taichung Veterans General Hospital /Division of Nephrology

Taichung Veterans General Hospital /Division of Nephrology

China Medical University Hospital /Division of Nephrology

China Medical University Hospital /Division of Nephrology

China Medical University Hospital /Division of Nephrology

Asia University Hospital /Division of Nephrology

Contact Information

c-IRB

Chih-Hsiang Chang

Email:franwisandsun@gmail.com

TEL:0975-368130 ext